About Us

pharmaand GmbH (pharma&), a privately owned global company, headquartered in Austria, Vienna, aspires to breathe new life into proven medicines. Since its inception in 2017, pharma& has been dedicated to preserving the availability and fostering the further development of essential medicines worldwide to leave no patient behind. Accessing effective medicine is a primary goal for both healthcare providers and patients, and it can be devastating when those medicines are no longer available.

As a commercial-stage company, pharma& has aggregated 10+ specialty pharmaceutical therapeutics. Whether a former blockbuster or niche medicine, pharma& acquires the worldwide rights to these needed medicines.

Our worldwide network of partners, combined with pharma&’s presence in 15 countries with a geographic focus on Europe and the U.S., spans all pharmaceutical functions, making us an integration powerhouse across the development continuum. This includes full value chain capabilities covering the entire product life cycle.

As pharma& continues to evolve, our focus remains clear: maintaining and developing essential medicines for the eligible patients who depend on them.

Portfolio of Essential Medicines

As medicines become more mature, they are often given lower priority within a company portfolio and eventually may be discontinued. Our global strategy focuses on acquiring the worldwide rights to specialty treatments to secure long-term access to essential medicines across various specialized therapy areas.

pharma& continues to adapt and grow its portfolio across a wide range of therapy areas, with an increasing focus on hematological and oncological treatments. pharma&’s portfolio of essential medicines includes:

Integrated Organization with Global Reach

With its subsidiaries, joint ventures, and partners, pharma& seeks to be a fully integrated organization. This unique approach enables pharma& to provide its portfolio of medicines to eligible patients worldwide by spanning the continuum of research and development, in-house product and API manufacturing, distribution via its global partner network, healthcare provider engagement, and patient services through U.S. Market Access.

pharma& directly engages with healthcare providers in Europe and the U.S. to promote approved products in approved markets and indications.

By providing supply to partners, pharma& distributes its medicines globally.

pharma&’s joint venture with Summit SD LLC and Heritage Specialty Pharmacy LLC supports the distribution and provision of patient support services within the U.S.

Loba biotech GmbH, a wholly owned subsidiary of pharma&, produces the active pharmaceutical ingredient (API) for Pegasys® (peginterferon alfa-2a).

Learn more

Our Exceptional Growth Journey

Unique Ultra-Lean, Virtual Business Model

2017

Early Days

Corporate Formation

2018 – 2021

Off-Patent Portfolio Acquisition

Anafranil®, Androskat®, Asacol®, Dridase®, Emselex®, Euphyllin®, Faktu®, Levact®

Expansion Into Global Markets

2021

Integration Powerhouse

Pegasys® Acquisition from F. Hoffman-La Roche Ltd. (Roche)
Loba biotech Acquisition

Innovative Commercial Engine, Pricing and Market Access Expertise, Medical Team, and Clinical Development Capabilities

2022

Farydak® Acquisition

Commercial Building Block Begins with the Integration of UK Commercial Structure
pharma& Affiliates Initiated

2023

Rubraca® Acquisition

Onboarding of U.S. and Europe Commercial, Europe Medical, Europe Pricing and Market Access, and Clinical Development Talent

2024

pharma& Acquires Global Rights to Satraplatin from Dayton Therapeutics
Promotional Agreement with Tolmar for Certain Rubraca U.S. Indications

Organic Development Pipeline and Reaping Organization Synergies

Beyond

As pharma& continues to evolve, our focus remains clear: breathing new life into proven medicines to ensure that no patient is left behind. Stay informed on what’s next.

Breathing New Life
Into Proven Medicines